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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of prospective pharmacogenetic screening to reduce drug-associated skin reactions in a patient population.
B A C K G R O U N D
We have explained some terms we have used in a glossary. Please
see Table 1.
Description of the condition
Some drugs may cause skin rashes that vary in their severity and
incidence. Skin reactions caused by drugs, often termed ’drug-in-
duced skin injury’ (DISI), are common (carbamazepine-induced
skin rash has a 10% incidence rate (Marson 2007)); they present
with a range of clinical manifestations ranging from a mild macu-
lopapular skin rash to life-threatening skin rashes such as Stevens-
Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
(Pirmohamed 2004; Roujeau 1987). The most severe forms are
very rare, but these may result in up to 30% mortality. Less severe
forms of hypersensitivity reactions are troublesome and may pre-
vent people from taking medications that are otherwise effective.
The mechanisms involved in the pathogenesis of these drug-in-
duced reactions are still poorly understood; however, immuno-
genetic and non-immune factors have been implicated. Recent ev-
idence suggests that drug-specific T-cells can be identified in indi-
viduals who previously experienced adverse drug reactions (ADRs)
to the culprit drug (Illing 2012).
Description of the intervention
There is increasing evidence from clinical trials that pretreatment
genetic testing may reduce the possibility of severe drug-induced
hypersensitivity (Chen 2011; Mallal 2008).
Figure 1 represents a diagram of decision-making informed by
genetic testing.
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Figure 1. Flowchart of interventions (genetic testing) and outcomes (skin rash) in a patient population
prescribed drug X
To date, the strongest association with drug-induced skin injury
has been reported with genetic variants in the human leuko-
cyte antigens (HLA) (Amstutz 2013; Chung 2004; Hetherington
2002; Hung 2005; Mallal 2002; McCormack 2011; Ozkaya-
Bayazit 2001). Human leukocyte antigens are cell surface proteins
involved in presenting antigens to the immune system. They are
encoded by most polymorphic genes in the human genome. How-
ever, different genetic markers are associated with hypersensitivity
in different populations, and the effect size varies in different eth-
nicities. Also, there is evidence that some common factors could
predispose to DISI irrespective of the underlying drug aetiology.
In addition, it is possible that different severity phenotypes can
share the same predisposing factor.
Table 2 shows reported associations between hypersensitivity re-
actions, which include skin injury and genetic variants in HLA
genes.
How the intervention might work
Two recent clinical trials suggested that pretreatment genetic test-
ing could reduce the possibility of severe hypersensitivity induced
with an anti-AIDSdrug, abacavir (Mallal 2008), and an antiepilep-
tic drug, carbamazepine (Chen 2011).
Patients who have a clinical requirement for a particular drug
treatment can be stratified on the basis of a genetic test. Those
who test positive for the risk marker are not prescribed the culprit
drug, while those who test negative are safe to take the medicine
of interest. In this way, it may be possible to reduce the incidence
of severe drug skin reactions in the genotyped group compared
to the randomly assigned group of patients who are not offered
genetic testing, but for whom decision on drug choice is based on
traditional clinical and biochemical parameters.
Why it is important to do this review
Adverse drug reactions affecting the skin are common; they can
have high morbidity and mortality and are a burden for healthcare
systems around the world. If we were able to predict them on the
basis of a simple genetic test, it should be possible to prevent these
reactions with one of the following approaches:
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1. by prescribing alternative therapy if available;
2. by informing patients and healthcare providers; or
3. by informing drug developers in order to improve drug
design and future drug development.
We aim to assess current research evidence to determine whether
prospective pharmacogenetic screening is effective in reducing
drug-associated skin reactions.
O B J E C T I V E S
To assess the effects of prospective pharmacogenetic screening to
reduce drug-associated skin reactions in a patient population.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs), which may
be single-blind or unblinded.
Types of participants
People (adults and children of either gender) who are pre-
scribed drugs known to cause delayed type hypersensitivity reac-
tions. These include antiepileptic drugs, antiretrovirals, antigout
drugs, and antibiotics such as beta-lactams (penicillin, amoxicillin,
piperacillin, cephalosporins) and sulphonamides (sulphamethox-
azole and trimethoprim).
Types of interventions
We will consider genetic testing for any genetic variants associated
with hypersensitivity reactions using all available techniques to
determine individual genotypes. The intervention is a randomly
allocated genetic test; if the test is positive, a drug that can cause
hypersensitivity is avoided.
Types of outcome measures
We will base core outcome measures on several papers describ-
ing clinical classification of drug-induced skin reactions, including
the recently published paper entitled ’Phenotype standardisation
for immune-mediated drug-induced skin injury’ (Pirmohamed
2011), as well as earlier papers by the RegiSCAR (European
Registry of Severe Cutaneous Adverse Reactions) consortium
(Bouvresse 2012; Kardaun 2013; Sekula 2011).
We will assess clinically defined hypersensitivity reaction, im-
munologically confirmed hypersensitivity reaction (if skin patch
testing or lymphocyte proliferation assay data are available), and
long-term sequelae (including ophthalmologic, cutaneous, or liver
damage, etc).
We have provided a full list of clinically relevant outcomes and
distinction between primary and secondary outcomes inAppendix
1.
Primary outcomes
1. The incidence of severe drug-induced skin rash.
2. Long-term sequelae (including ophthalmologic, cutaneous,
or liver damage, etc) up to 12 months after the severe drug-
induced skin rash.
Secondary outcomes
1. Hospitalisation for drug-induced skin reaction within 3
months of exposure to the drug.
2. Clinical phenotypes of hypersensitivity reactions (organ
specific and systemic manifestations) including the following:
• SJS/TEN (Stevens-Johnson syndrome, toxic epidermal
necrolysis);
• AGEP (acute generalised exanthematous pustulosis); and
• HSS (hypersensitivity syndrome).
Additional terminology for HSS includes the following: Drug-
induced hypersensitivity syndrome (DIHS), Drug reaction with
eosinophilia and systemic symptoms (DRESS), andDrug-induced
delayed multiorgan hypersensitivity syndrome.
Search methods for identification of studies
We aim to identify all relevant randomised controlled trials (RCTs)
regardless of language or publication status (published, unpub-
lished, in press, or in progress).
Electronic searches
We will search the following databases for relevant trials:
• the Cochrane Skin Group Specialised Register;
• the Cochrane Central Register of Controlled Trials
(CENTRAL) in The Cochrane Library;
• MEDLINE via OVID (from 1946);
• EMBASE via OVID (from 1974); and
• LILACS (Latin American and Caribbean Health Science
Information database, from 1982).
We have devised a draft search strategy for randomised con-
trolled trials (RCTs) for MEDLINE (OVID), which is displayed
in Appendix 2. This will be used as the basis for search strategies
for the other databases listed.
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Trials registers
We will search the following trials registers:
• The metaRegister of Controlled Trials (www.controlled-
trials.com).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov).
• The Australian New Zealand Clinical Trials Registry (
www.anzctr.org.au).
• The World Health Organization International Clinical
Trials Registry platform (www.who.int/trialsearch).
• The EU Clinical Trials Register (
www.clinicaltrialsregister.eu/).
Searching other resources
References from included studies
We will check the bibliographies of included studies for further
references to relevant trials.
Adverse Effects
We will not perform a separate search for adverse effects of the
target intervention. However, we will examine data on adverse
effects from the included studies we identify.
Data collection and analysis
We plan to include at least one ’Summary of findings’ table in
our review. In this, we will summarise the primary outcomes for
the most important comparison. If we feel there are several major
comparisons or that our findings need to be summarised for dif-
ferent populations, we will include further ’Summary of findings’
tables.
Selection of studies
Two review authors (AA and AJ) will independently assess stud-
ies for inclusion; they will independently screen all the titles and
abstracts of publications identified by the searches to assess their
eligibility. We will assess the full text of eligible citations for inclu-
sion. We will exclude publications that do not meet the criteria at
this stage and prepare a table of ’Characteristics of excluded stud-
ies’ to clearly differentiate between those studies that are not at
all relevant and those that may not fulfil the criteria for inclusion
but may be considered relevant by some readers. We will reach
consensus on the selection of trials and the final list of studies.
Data extraction and management
Two authors (AA and AJ) will independently extract data from
included studies and resolve disagreements by discussion. If con-
sensus is not reached, they will consult a third author (MP). We
will collect the following information on study characteristics and
methods: study design; inclusion and exclusion criteria; setting;
country; language of publication; ethnicity of participants; control
population (exposed to the culprit drug or healthy population); de-
scription of genotyping techniques used; genotyping quality con-
trol, which will include deviation from Hardy-Weinberg equilib-
rium (Hardy-Weinberg equilibrium is a crucial concept in popu-
lation genetics; it predicts how gene frequencies will be inherited
from generation to generation and is used as a measure of quality
of genetic tests) and genotype call rate; age; gender; concomitant
medications; time from exposure to culprit drug to skin reaction;
type of skin reaction; location of skin lesion; duration; treatment;
sequelae; other manifestations indicating systemic involvement;
and laboratory tests.
Assessment of risk of bias in included studies
All review authors will assess the risk of bias of three studies as a
pilot to ensure we are using consistent methods. AA and AJ will
then independently assess the risk of bias in each trial according to
the approaches described in theCochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). Specifically, we will use
The Cochrane Collaboration’s tool for assessing risk of bias (Table
8.5.a in the Cochrane Handbook for Systematic Reviews of Interven-
tions), which is based on seven domains (sequence, generation,
allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data, selec-
tive outcome reporting, and other issues). The tool allows for the
risk of bias to be assessed as ’low’, ’high’, or ’unclear’ (indicating
lack of information or uncertainty over the potential for bias). An
additional author (MP) will assess any disagreements.
Measures of treatment effect
We will use statistical methods in accordance with theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011)
to measure treatment effect. We will use mean difference (MD)
with 95% confidence interval (CI) for continuous data or indeed
standardised mean difference (SMD) with 95%CI where all stud-
ies report an outcome using similar scales. We will use risk ratio
(RR) with 95% CI for dichotomous data.
Unit of analysis issues
We will take care to avoid a unit of analysis error due to repeated
observations on participants, multiple treatments, or re-occurring
events. We will also consider issues in cluster randomised tri-
als, such as recruitment bias, baseline comparability of clusters,
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and number of clusters, and make sure that appropriate statistical
methods are used that take into account weighting, etc.
Dealing with missing data
We will consider the possible different types of missing data. We
will deal with missing studies and the associated risk of bias by
assessing for publication bias, whilst we will deal with missing
outcomes and the associated risk of bias by assessing for selective
reporting (see Assessment of reporting biases section).
In the event of missing summary data, we will contact the study
author if data required to calculate outcomes of interest are miss-
ing. If no further data are available, we will not include the study
in the meta-analysis. However, we will report the limited results
from the study in narrative form in the results section and consider
whether they are consistent with the results of themeta-analysis for
that outcome. Also, where appropriate, we will make assumptions
about the missing data (e.g. assuming all missing values to have
a particular value, e.g. an adverse event) and conduct sensitivity
analyses to test how sensitive the analyses are to our assumptions.
We will address the potential implications of the missing data in
the Discussion section.
Assessment of heterogeneity
We will assess the extent of heterogeneity using the I² statistic.
We will use the following thresholds for the interpretation of the
I² statistic:
• 0% to 40% = might not be important;
• 30% to 60% = moderate heterogeneity;
• 50% to 90% = may represent substantial heterogeneity; and
• 75% to 100% = considerable heterogeneity.
If we do ameta-analysis, we shall report the I² statistic and interpret
the two data together.
Assessment of reporting biases
We will assess biases, including publication bias, ’time-lag’ bias,
outcome reporting bias, language bias, and citation bias. We will
use a funnel plot, Begg test, and Egger test to evaluate publication
bias (Begg 1989; Egger 1998).We will only carry out tests for fun-
nel plot asymmetry when there are at least 10 studies included in
the meta-analysis, because when there are fewer studies, the power
of the tests is too low to distinguish chance from real asymmetry.
Data synthesis
If there is no significant clinical heterogeneity, we will synthesise
the results in meta-analyses. We will synthesise data according to
type of intervention (e.g. genotype test). We will use a random-
effects model.
Where events are rare, a random-effects approach may be inap-
propriate. Where events are rare, extra care will be taken to adopt
appropriate methods of meta-analysis as recommended in the
Cochrane Handbook for Systematic Reviews of Interventions (section
16.9), since many meta-analysis methods are suboptimal where
events are rare through results being biased, confidence intervals
being too wide, or power being too low. Choice of method will
be guided by control group risk, likely treatment effect size, and
consideration of balance in numbers of treated and control partic-
ipants in the constituent studies. Where the control groups differ,
e.g. they are drawn from a healthy population or from a popula-
tion of people treated with the culprit drug but without any ad-
verse effects, we will conduct separate analysis. We will use Review
Manager to undertake the meta-analyses.
Subgroup analysis and investigation of heterogeneity
Where there is substantial heterogeneity, we will explore the causes
by way of subgroup analyses. Indeed, some HLA genetic variants
are associated with a high risk of drug-induced skin reactions, so
interventions would only be given to the appropriate subpopula-
tion.
We will consider the following:
• participant factors (age, ethnicity, ADR classification, and
comparability of participant groups); and
• trial design issues (genotyping methodology and quality
control, blinding, drugs included, and drug dosage and duration
of use).
Sensitivity analysis
We will evaluate the robustness of the results of the meta-analyses
by removing trials of low methodological quality as defined by
their risk of bias.
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A D D I T I O N A L T A B L E S
Table 1. Glossary of terms
Term Explanation
Allele One of two or more alternative forms of a gene at corresponding sites (loci) on homologous chro-
mosomes
Hardy-Weinberg equilibrium This states that allele and genotype frequencies in a population will remain constant from generation
to generation in the absence of other evolutionary influences
HLA Human leukocyte antigen: a group of protein molecules located on bone marrow and other cells that
can provoke an immune response
Hypersensitivity A state of altered reactivity in which the body reacts with an exaggerated immune response to a
foreign substance, such as a drug
Polymorphic A variation in the DNA that is too common to be due merely to new mutation. A polymorphism
must have a frequency of at least 1% in a population
Maculopapular rash A rash with both macules (flat and coloured like a freckle) and papules (a small raised spot)
Table 2. Associations between drug-induced skin injury and genetic variants in the HLA genes
Drugs associated with
skin injury





Allopurinol Antiuric acid B*5801 Han Chinese Hung 2005
- - - Thai Tassaneeyakul 2009a
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Table 2. Associations between drug-induced skin injury and genetic variants in the HLA genes (Continued)
- - - Japanese Kaniwa 2008
- - - Malay Ding 2010
Carbamazepine Antiepileptic B*1502 Han Chinese Cheung 2013; Chung 2004;
Chong 2013; Hung 2006;
Man 2007




- - - Malay Ding 2010
- - - Indian Mehta 2009
- - A*3101 White Amstutz 2013; McCormack
2011;
- - A*3101 Japanese Ozeki 2011
Phenytoin Antiepileptic B*1502 Han Chinese Hung 2010; Man 2007




A2, B12 White Roujeau 1987




Abacavir Antiretroviral B*5701 White Hetherington 2002; Hughes
2004; Mallal 2002; Mallal
2008; Martin 2004
- - - African Americans Hughes 2004a; Saag 2008
Aminopenicillins Antibiotic A2, Drw52 White Romano 1998
Nevirapine Antiretroviral DRB1*01 White - Australian Martin 2005
- - DRB1*01 White - French Vitezica 2008
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Table 2. Associations between drug-induced skin injury and genetic variants in the HLA genes (Continued)
- - Cw8, B14 White - Italian Littera 2006
- - Cw8 Japanese Gatanaga 2007
- - B*3505 Thai Chantarangsu 2009
- - Cw4 Thai Likanonsakul 2009
- - C*0404 Black African Carr 2013
- - Cw*04 Chinese Gao 2012
Aspirin NSAIDS DRB1*1302,
DQB1*0609
- Kim 2005; Palikhe 2008
- NSAIDS DR11 - Quiralte 1999
Iodine contrast media - DR White - Spanish Torres 2008
Paraphenylenediamine Hair dye DP White - German Sieben 2002
Gold sodium thiomalate Treatment of rheuma-
toid arthritis
DR5 White - Spanish Rodriguez-Pérez 1994
Lamotrigine Antiepileptic B*5801, A*6801 White Kazeem 2009
Trichloroethylene Industrial solvent, dry
cleaning
B*1301 Japanese Li 2007; Watanabe 2010
Fixed drug eruptions
Co-trimoxazole Antibiotic A30, B13, Cw6 White - Turkish Ozkaya-Bayazit 2001
Feprazone Analgesic B22 - Pellicano 1997
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A P P E N D I C E S
Appendix 1. Outcomes adapted from Pirmohamed 2011
Primary outcome:
• Drug-induced skin reaction (yes, no)
Secondary outcome:
• Clinical phenotype:
SJS/TEN (Stevens-Johnson syndrome, toxic epidermal necrolysis)
◦ Skin detachment 1% to 10% (SJS), 10% to 30% (overlap syndrome), and > 30% (TEN)
◦ Severe, often hemorrhagic, erosions of mucous membranes
◦ Other manifestations indicating systemic involvement (e.g. fever, liver chemistry elevations, intestinal and pulmonary
manifestations, or the presence of lymphopenia)
◦ Severe pain and tenderness in the skin
◦ Target lesions, representing the degree of epidermal necrosis
AGEP (acute generalised exanthematous pustulosis)
◦ Acute widespread edematous erythema followed by a sterile pustular eruption. Often the pustules are first localised in the
neck, groin, and axillae, and later become widely disseminated
◦ Fever (temperature > 38 °C)
◦ Neutrophilia with or without a mild eosinophilia
HSS (Hypersensitivity syndrome)
◦ Additional terminology includes Drug-induced hypersensitivity syndrome (DIHS), Drug reaction with eosinophilia and
systemic symptoms (DRESS), Drug-induced delayed multiorgan hypersensitivity syndrome
◦ Variable skin manifestations; exanthema are most common








◦ Eosinophilia, atypical lymphocytes, agranulocytosis, thrombocytopenia, haemolytic anaemia, aplastic anaemia
◦ Lymphadenopathy, pseudolymphoma
Appendix 2. MEDLINE (OVID) search strategy
1. exp Exanthema/
2. exanthema.ti,ab.
3. (rash or rashes).ti,ab.
4. drug induced skin injury.ti,ab.
5. exp Drug Hypersensitivity/ge, pc [Genetics, Prevention & Control]




10. exp Drug Toxicity/ge, pc [Genetics, Prevention & Control]
11. drug toxic$.ti,ab.
12. adverse drug reaction$.ti,ab.
13. toxic epidermal necrolysis.ti,ab. or exp Epidermal Necrolysis, Toxic/
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14. stevens johnson syndrome.ti,ab. or exp Stevens-Johnson Syndrome/
15. exp Acute Generalized Exanthematous Pustulosis/
16. Acute Generalized Exanthematous Pustulosis.ti,ab.
17. erythema multiforme.ti,ab. or exp Erythema Multiforme/
18. dress syndrome.ti,ab.
19. “Drug Reaction with Eosinophilia and Systemic Symptoms”.ti,ab.
20. “Drug Rash with Eosinophilia and Systemic Symptoms”.ti,ab.
21. or/1-20
22. exp Genetic Testing/
23. genetic test$.ti,ab.
24. exp Pharmacogenetics/
25. (pharmacogenomic$ or pharmacogenetic$).ti,ab.
26. screening.ti,ab.
27. patch test$.ti,ab.
28. exp Patch Tests/
29. exp HLA Antigens/
30. hla allele$.ti,ab.
31. exp Polymorphism, Genetic/
32. genetic polymorphism$.ti,ab.
33. exp Genetic Variation/
34. (genetic variant$ or genetic variation$).ti,ab.
35. or/22-34
36. randomized controlled trial.pt.
37. controlled clinical trial.pt.
38. randomized.ab.
39. placebo.ab.
40. clinical trials as topic.sh.
41. randomly.ab.
42. trial.ti.
43. 36 or 37 or 38 or 39 or 40 or 41 or 42
44. exp animals/ not humans.sh.
45. 43 not 44
46. 21 and 35 and 45
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